复发与治疗失败患者结核分枝杆菌基因型分析

摘要/Abstract

摘要： 目的分析复发和治疗失败患者结核杆菌基因型并进行病原学探讨。方法以2000年1月—2007年12月在北京市结核病胸部肿瘤研究所2次住院相邻时间间隔至少在6个月以上、有分离菌株的肺结核病患者作为研究对象。应用结核分枝杆菌基因分型方法对患者初次和第2次治疗的菌株进行分型并比较。结果24例结核病患者入选本研究。在完成初次治疗的5人中，其前后分离株的基因型均相同；在另19例患者（8例丢失、11例治疗失败）中，有2例(10.5%)患者其分离株的基因型与第1次不同；其余17例（89.5%）患者前后2次分离株的基因型相同。结论内源发病是复发的主要原因,失败和丢失病例中少数存在再感染情况。

关键词: 结核，肺/治疗, 治疗失败, 分枝杆菌, 结核, 基因型

Abstract: ObjectiveTo analyze the genotypes of M. tuberculosis from the TB patients with recurrence or treatment failure. MethodsTuberculosis (TB) inpatients who had strains isolated from two successive episodes separated for at least 6 months were selected from Beijing Tuberculosis & Thoracic Tumor Institute during January 2000 to December 2007. The sequential isolates from the patients were analyzed by M. tuberculosis genotyping Methods to find out if the profiles matched. Results24 patients recruited into the study. The genotype patterns of recurrent M.tuberculosis isolates from the 5 patients previously completed treatment exhibited identical genotypes, indicating endogenous reactivation. Of 19 isolates from 8 patients defaulted from treatment and 11 patients with treatment failure, genotype patterns of 2 isolates (10.5%) did not match with those of the corresponding initial isolates, indicating reinfection. Isolates from the remaining 17 （89.5%） patients had identical genotype profiles results, suggesting treatment failure.ConclusionsThe endogenous reactivation and treatment failure may be a main cause for the recurrence of TB cases.

Key words: Tuberculosis,pulmonary/therapy, Treatment failure, Mycobacterium tuberculosis, Genotype

王胜芬,赵雁林,周杨,赵冰,赵立平,夏辉,董玲玲. 复发与治疗失败患者结核分枝杆菌基因型分析[J]. 中国防痨杂志, 2009, 31(8): 464-468.

Wang Shengfen, Zhao Yanlin, ZhouYang, Zhao Bing, Zhao Liping, XiaHui, Dong Lingling.. Genotypes of M tuberculosis from the TB patients with recurrence or treatment failure[J]. Chinese Journal of Antituberculosis, 2009, 31(8): 464-468.

参考文献

[1] Combs DL, O’Brien RJ, Geiter LJ. USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, and acceptability. The report of final results[J]. Ann Intern Med, 1990,112(6): 397-406.
[2] Hong Kong Chest Service/British Medical Research Council. Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 months[J]. Am Rev Respir Dis, 1991,143(4): 700-706.
[3] Barnett GD, Grzybowski S, Styblo K. The current risk of contracting evolutive tuberculosis, in Saskatchewan, according to the state of previous tuberculin tests and x-ray image[J]. Bull Int Union Tuberc, 1971, 45: 55-79.
[4] Canetti G, Sutherland I,Svandova E. Endogenous reactivation and exogenous reinfection: their relative importance with regard to the development of non-primary tuberculosis[J]. Bull Int Union Tuberc, 1972, 47:116-134.
[5] Kim BJ, Lee SH, Lyu MA, et al. Kim BJ, Lee SH, Lyu MA, Kim SJ, Bai GH, Chae GT, Kim EC, Cha CY, Kook YH. Identification of mycobacterial species by comparative sequence analysis of the RNA polymerase gene (rpoB) [J]. J Clin Microbiol, 1999, 37(6): 1714-1720.
[6] Frothingham R, and WA Meeker-O’Connell. Genetic diversity in the Mycobacterium tuberculosis complex based on variable numbers of tandem DNA repeats[J]. Microbiology, 1998, 144:1189-1196.
[7] Kamerbeek J, Schouls L, Kolk A, van Agterveld M, van Soolingen D, Kuijper S, Bunschoten A, Molhuizen H, Shaw R, Goyal M, van Embden J. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology[J]. J Clin Microbiol, 1997, 35(4): 907-914.
[8] van Embden JD, Cave MD, Crawford JT, Dale JW, Eisenach KD, Gicquel B, Hermans P, Martin C, McAdam R, Shinnick TM. Strain Identification of Mycobacterium tuberculosis by DNA Fingerprinting: Recommendations for a Standardized Methodology[J]. J Clin Microbiol, 1993, 31(2): 406-409.
[9] van Rie A, Warren R, Richardson M, Victor TC, Gie RP, Enarson DA, Beyers N, van Helden PD. Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment[J]. N Engl J Med, 1999,341(16): 1174-1179.
[10] Jasmer RM, Bozeman L, Schwartzman K, Cave MD, Saukkonen JJ, Metchock B, Khan A, Burman WJ; Tuberculosis Trials Consortium.Recurrent tuberculosis in the United States and Canada relapse or reinfection？[J]. Am J Respir Crit Care Med, 2004, 170(12): 1360-1366.
[11] Shamputa IC, Van Deun A, Salim MA, Hossain MA, Fissette K, de Rijk P, Rigouts L, Portaels F. Endogenous reactivation and true treatment failure as causes of recurrent tuberculosis in a high incidence setting with a low HIV infection[J]. Trop Med Int Health, 2007,12(6): 700-708.
[12] 沈国妙, 薛桢, 沈鑫, 桂晓红, 王奕峰, 孙斌, 沈梅, 梅建, 高谦.利用结核分枝杆菌基因型分型技术研究外源性再感染在结核病复发中的作用[J].中华结核和呼吸杂志，2006，29（2）：79-82.
[13] Sonnenberg P, Murray J, Shearer S, Glynn JR, Kambashi B, Godfrey-Faussett P. Tuberculosis treatment failure and drug resistance-same strain or reinfection?[J]. Trans R Soc Trop Med Hyg, 2000, 94(6): 603-607.
[14] Bandera A, Gori A, Catozzi L, Degli Esposti A, Marchetti G, Molteni C, Ferrario G, Codecasa L, Penati V, Matteelli A, Franzetti F. Molecular epidemiology study of exogenous reinfection in an area with a low incidence of tuberculosis[J]. J Clin Microbiol, 2001, 39(6): 2213-2218.

[1]	许岩, 路希维, 蔡春葵, 孙诗学, 顾晓峰, 于洋, 李刚, 王颖. 治疗失败耐多药肺结核患者CT征象演变的回顾性分析[J]. 中国防痨杂志, 2020, 42(6): 549-557.
[2]	梁小烟, 林玫, 梁大斌, 蓝如束, 覃慧芳, 叶婧, 黄莉雯. 广西壮族自治区耐多药结核分枝杆菌耐药情况与基因型特征分析[J]. 中国防痨杂志, 2020, 42(6): 578-582.
[3]	洪创跃, 杨婷婷, 李金莉, 李霜君, 吴利凯, 杨争, 谭卫国. 深圳市耐多药结核分枝杆菌耐药基因突变特征分析[J]. 中国防痨杂志, 2020, 42(6): 583-589.
[4]	李邦银,蒲育,何敏,蒋曦,李海,刘林,何磊,环明苍,蔡玉郭,刘勇. 脊柱结核术后未愈的影响因素分析[J]. 中国防痨杂志, 2019, 41(5): 510-514.
[5]	钟鑫,张强,许祖远,方德健. 前路翻修术对胸腰椎结核后路固定术后失败的治疗效果[J]. 中国防痨杂志, 2019, 41(5): 521-528.
[6]	刘晓俊,余枫华,余云芳,纪律,周攀,赵雁林. 宜昌地区结核分枝杆菌基因分型与成簇特征分析[J]. 中国防痨杂志, 2019, 41(3): 308-314.
[7]	彭英,唐鹭,裴新发,张学志,林百丰,陈丽,于艳玲,李发滨. 黑龙江省五常市结核分枝杆菌基因型及传播特征[J]. 中国防痨杂志, 2019, 41(3): 315-321.
[8]	谢彤,王春花,赵慧,巨韩芳,穆成,王志锐,孙蕊. 天津市监狱羁押人员中结核病患者临床分离菌株的基因型分析[J]. 中国防痨杂志, 2019, 41(3): 361-363.
[9]	董文竹,王政,文舒安,张婷婷,霍凤敏,董玲玲,李云絮,赵立平,黄海荣,高飞,逄宇. 耐多药及广泛耐药MTB菌株对SQ109的耐药性及其与北京基因型的关系[J]. 中国防痨杂志, 2018, 40(5): 506-511.
[10]	谢彤,孙蕊,巨韩芳,王春花,穆成,王志锐,赵慧. 结核分枝杆菌北京基因型菌株大片段的多态性研究[J]. 中国防痨杂志, 2018, 40(3): 269-273.
[11]	林淑芳,魏淑贞,赵永,林建,林勇明. 福建省耐多药结核分枝杆菌对吡嗪酰胺的耐药水平与基因型特征分析[J]. 中国防痨杂志, 2018, 40(12): 1330-1334.
[12]	胡彦,刘洁,沈静,朱大冕,冯鑫,陈林,詹建,欧喜超,周杨,赵雁林. 重庆地区耐多药结核分枝杆菌对氟喹诺酮类药物耐药的相关基因特征分析[J]. 中国防痨杂志, 2018, 40(10): 1060-1065.
[13]	陈素婷,黄明翔,胡严杰,尚媛媛,梁倩,付育红,黄海荣. 荧光探针熔解曲线法检测结核患者N-乙酰基转移酶2基因型分布的应用评价[J]. 中国防痨杂志, 2018, 40(1): 63-67.
[14]	包海洋，曹旭东，秦莲花，等. 北疆地区结核分枝杆菌基因分型及耐药性分析[J]. 中国防痨杂志, 2016, 38(2): 110-115.
[15]	孟庆琳，王玉峰，逄宇，等. 耐多药结核分枝杆菌耐药相关基因突变特征分析[J]. 中国防痨杂志, 2016, 38(2): 116-121.